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 Facial skin cancer is common, and its treatment affects patient’s health-related 
quality of life (HRQoL), as demonstrated by patient reported outcome measures 
(PROMs). In this study we Anglicise and validate the novel FACE-Q Skin Cancer 
module for the UK population. 
 Anglicisation of the FACE-Q Skin Cancer module followed international 
guidance for cross-cultural adaptation. Cognitive interviews were performed, 
producing a reconciled and harmonised version for validation. Patients undergoing 
facial skin cancer excision were prospectively recruited and asked to complete the 
anglicised FACE-Q Skin Cancer module, along with the Skin Cancer Index (SCI) and 
European Quality of Life Five Dimensions (ED-5D) questionnaire, pre-operatively and 
6-8 weeks post-operatively. Data were analysed using classical test theory. Ethical 
approval was received (REC: 16/WM/0445). 
 One hundred and ten patients were recruited between August 2017 and July 
2018. Internal consistency was high (Cronbach’s alpha 0.867-0.967). All subscales had 
a single factor solution using principal component analysis. Construct validity, as 
measured between the FACE-Q subscales and SCI subscales was good, with >75% of 
a priori predictions confirmed. Pearson’s r for item-total correlation was >0.80 for 
several items and significant ceiling effects were shown in 7 of the 10 subscales, 
suggesting some item redundancy. 
 The UK version of this well-designed PROM demonstrates good face and 
construct validity. There is however a degree of redundancy within the scales and 
further work using Rasch analysis on a larger sample will help address this. 
 


























 Skin cancer is the commonest malignancy worldwide1, with the majority 
occurring on sun-exposed sites such as the face2. While mortality is generally low, 
especially for non-melanoma skin cancer (NMSC)3,4, there is often a considerable 
psychological burden associated with anxiety relating to a cancer diagnosis5 and 
concerns over visible scarring6.  
 In order to improve global outcomes for patients with skin cancer it is important 
that a holistic approach to their health-related quality of life (HRQoL) is taken. This 
requires the assessment of HRQoL in these patients before, during and after treatment. 
One method for assessing HRQoL is the use of patient-reported outcome measures 
(PROMs). PROMs are standardised and validated questionnaires, completed by 
patients, that capture one or more aspects of their health and wellbeing7,8. They are 
considered by the United Kingdom (UK) Department of Health as the current best 
method for quantifying a patient’s clinical experience, although their use clinically is 
still sporadic. 
 A recent systematic review demonstrated a paucity of appropriately designed 
and well validated PROMs for facial skin cancer, although evidence was found for a 
newly developed instrument that had considerable potential9. The FACE-Q Skin 
Cancer module has since been validated in an initial population of 20910. Due to the 
importance of robust PROM data in both clinical and research settings the United States 
(US) Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) expect a PROM to be appropriately translated and adapted before use11,12. This 
paper therefore presents the results of the UK anglicisation and initial validation of the 
FACE-Q Skin Cancer module.  
 
Methods 
 The Patient Reported Outcomes In Skin Cancer Reconstruction (PROMISCR) 
study is a prospective anglicisation and validation study of the newly created FACE-Q 
Skin Cancer module. A study protocol was prospectively published13 and research 
ethics committee approval granted (REC: 16/WM/0445). A number of international 
methodological guidelines for cross-cultural adaptation exist14, with this study 
following those of the International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) Task Force15 and the Patient Reported Outcome Consortium16-18. 




 The aim of cross-cultural adaptation is to provide equivalence between the 
source language (the language in which the PROM was originally developed) and the 
target language (the new language into which it is to be translated). The degree of cross-
cultural adaptation required varies depending on the situation in which the adapted 
PROM is being used. Guillemin et al19 described five different scenarios where 
differing adaptation needs are required (Table 1). These range from the situation in 
which no adaptation is required, to full translation and cross-cultural adaptation. 
Anglicisation for the FACE-Q Skin Cancer module comes under scenario C, where the 
instrument requires cultural adaptation only (Table 1). Figure 1 demonstrates the steps 
performed in anglicisation. The FACE-Q Skin Cancer module used in this study was 
an early example provided by the original instrument developers, consisting of 88 items 
across 10 subscales. A copy of the original source language (US English) questionnaire 
was given to three plastic surgeons, one dermatologist and two health outcome measure 
specialists for review, with ‘Americanism’ removed and wording changed where 
confusing. Cognitive interviews were carried out with five patients in line with the 
minimum recommended number for anglicisation18 using the anglicised questionnaire 
and a basic interview plan. Further changes were made to the questionnaire following 
this, with a final harmonised version assessed for an appropriate level of readability 
before being taken forward for validation.     
    
Psychometric validation 
 Newly diagnosed patients were recruited from a single centre plastic surgery 
unit, the Welsh Centre for Burns and Plastics, Wales. Study details were provided to 
eligible patients and time given to consider inclusion before obtaining written consent. 
Patients were provided with a study pack containing a copy of the anglicised FACE-Q 
Skin Cancer module along with a copy of the Skin Cancer Index (SCI)20 and the generic 
European Quality of Life Five Dimensions (EQ5D) questionnaire21. A summary page 
of questions were also included to gain insight into their views on the questionnaire 
content. A post-operative questionnaire pack was sent to each patient six to eight weeks 
following surgery, with a reminder letter sent after two weeks to those who had not 
returned the second questionnaire pack. Inclusion in the PROMISCR study did not have 
any bearing on the treatment received by those recruited and they were free to withdraw 
at any point. 
 There are no general criteria for the required sample size when validating a 
PROM questionnaire22 although a sample size of between 50 and 100 has been 





• Skin cancer (all types included) of the face 
• Over 18 years of age 
• Active treatment with wide local excision of the lesion 
 
Exclusion criteria 
• Inability to consent to participation in the study 
• Known learning difficulties or dementia 
• English language not of a standard to understand and complete the questionnaire 
• Treatment of lesion with topical chemotherapy/laser or other methods that are 
not excisional 
• Free tissue reconstruction 
 
Data collection and psychometric analysis  
 All questionnaires were anonymised using a unique patient identifier with data 
acquisition and storage performed in accordance with the Data Protection Act 1998 and 
the 2018 General Data Protection Regulation (GDPR). Basic demographic data were 
collected on each patient along with diagnosis, past medical history, medication use 
and reconstruction used. Missing data were dealt with by using the mean of the 
completed items on a scale to replace missing values if less than 50% of the scale’s 
items were missing as per the developer’s guidelines. While missing data were reported 
in raw terms for the analysis of ‘missing data’, all other areas of data analysis used a 
more complete data set with mean imputation having been performed. We followed 
published standards on the minimization and reporting of missing data where 
appropriate24. Scores for each subscale were calculated by summing an individual’s 
answers for that subscale and then converting this to a Rasch transformation score using 
tables provided by the developer. Questionnaire and clinical data were input into 
Statistical Package for Social Sciences (SPSS) software V.22 (IBM Analytics, NY, 
USA) for analysis. Significance was taken as p < 0.05 unless stated otherwise.  
 Due to the subscale nature of the FACE-Q questionnaire the majority of data 
analysis was done at the subscale level. Psychometric analysis followed guidance by 
the Scientific Advisory Committee of the Medical Outcomes Trust25 and methods 
outlined by Streiner and Norman22. Psychometric validation is covered 
elsewhere22,26,27, but briefly the following were performed.  
 
1. Item piloting and underlying dimensions 
Missing data values were calculated for each item to assess if respondents were 
preferentially leaving out specific items.  
Floor and ceiling effect are a measure of how skewed the data are. If > 15% of 
respondents score the lowest or highest score the scale is said to have a floor or ceiling 
effect, respectively. 
Internal consistency is a measure of the homogeneity of a scale and therefore can be 
used to interrogate the items for their worth within a scale22. Cronbach’s alpha is used 
to measure internal consistency, with a value of 0.7 used as the minimum accepted 
value22.  
Item-total correlations were assessed using Pearson’s correlation (r), with item-total 
correlation of less than 0.2 or greater than 0.8 considered for removal22,28. 
Principal component analysis (PCA) was applied to the pre-operative data to identify 
the underlying ‘components’ or ‘factors’ that make up individual subscales. PCA was 
performed using the Direct Oblimin rotation technique to determine which items 
associate with one another into factors29. Kaiser’s rule where only factors with an 
eigenvalue of ≥ 1.0 are retained was used30. Items were considered for removal if their 
loading onto a factor was < 0.4. Finally, Horn’s parallel analysis was performed to 
confirm the number of factors present31.  
 
2. Validity 
 Construct validity is a measure of the correlation of the scale being tested to 
another instrument that is believed to assess the same or similar attributes. Pearson’s 
correlation coefficient (r) was used to assess the correlation between subscales of the 
FACE-Q Skin Cancer module and subscales on the SCI, along with correlations 
between one FACE-Q subscale and another. A number of a priori hypotheses were 
made with construct validity assumed if greater than 75% of these a priori hypotheses 
proved to be correct23. Interpretation of Pearson’s r values were based on guidelines by 
Cohen32; small (r = 0.10 to 0.29), medium (r = 0.30 to 0.49) and large (r = 0.50 to 1.0) 
 
3. Responsiveness 
 Responsiveness in the instrument is its ability to detect change in a patient’s 
condition when a change has occurred33. This was assessed by looking at group level 
change between pre-operative and post-operative questionnaires on subscales that were 
predicted to be influenced by the process of having surgery and interacting with the 






 The five patient participants had all been diagnosed and received treatment for 
a facial skin cancer within the last year, a sufficient length of time to have reflected on 
the process and no longer still be alarmed by the diagnosis, but not so long as to have 
forgotten the details of their treatment and how they felt. Words such as ‘color’ and 
‘behavior’ were identified as US English spelling and corrected. Other words such a 
‘sunscreen’ were deemed by many to be an American term and UK residents would be 
more likely to use ‘suncream’. Similarly the word ‘crooked’, while used in UK English 
it was felt that in the context of the assessment of a scar, few UK English speakers 
would use that term. A number of terms used in US medical settings were also 
unfamiliar to UK patients, such as the term ‘office staff’, which was converted to 
‘clerical staff’ to encompass those members of the team such as the clinic receptionist 
and consultant secretaries. Face validity was also deemed to be good for the FACE-Q 
Skin Cancer module by all those that reviewed it. 
 All results were combined and a reconciled version of the anglicised FACE-Q 
Skin Cancer module was created (Supplementary Figure 1). Readability of this 
finalised version was good, with an approximate reading age of US grade five or UK 
school age 8-9 years old across a number of readability scores (Supplementary Figure 




 A total of 113 patients were recruited. Three patients withdrew from the study 
after consenting to inclusion, stating the length of the questionnaire as their reason, 
resulting in a cohort of 110 patients completing the questionnaire pre-operatively 
(Table 2). Post-operative follow-up questionnaires were sent to all 110 patients. 
Seventy-three were returned, representing a 66% response rate. The mean length of 
time between operation (time point 1) and completion of a post-operative questionnaire 
(time point 2) was 8.6 weeks (SD = 3.8 weeks). 
 
Missing Data 
 Missing data were calculated from the raw scores obtained from each 
questionnaire. Table 3 summarises the range of missing data for each subscale of the 
FACE-Q Skin Cancer module and the SCI, with a number of the FACE-Q Skin Cancer 
subscales having greater than 20% missing data.  
 
 
Floor and ceiling effect 
 Floor and ceiling effects for transformed scores were calculated for each 
subscale (Table 4). Significant ceiling effects above the recommended 15% maximum 
can be seen for a number of the subscales. Skewedness was calculated, showing that 
all subscales apart from subscale 10 (symptom checklist), were skewed towards the 
higher end of the spectrum. Normal values for skewedness are between -1 and 1, 
therefore five of the subscales are skewed outside of this normal range.    
 
Internal consistency  
 Cronbach’s alpha was calculated for each individual subscale and ranged 
between 0.867 and 0.967. Only four subscales (cancer worry, satisfaction with 
information, sun protection behaviour and the symptom checklist) had Cronbach’s 
alphas of < 0.95.   
Item-item and item-total correlation 
 A large number of items (41/88, 46.6%) had an item-total correlation of > 0.80. 
There were, however, no items that had a Pearson’s r of < 0.20.    
 
Principal Component Analysis  
 Table 5 demonstrates the Kaiser-Meyer-Olkin (KMO), Bartlett’s test of 
sphericity, number of factors, eigenvalue and variance explained by this for each 
subscale. Single factor solutions were present for all subscales following Monte Carlo 
analysis. Strong loading is seen for all items in each scale, with values above 0.4, 
suggesting that none are candidates for removal.  
 
Construct validity  
 Construct validity between FACE-Q Skin Cancer subscales and subscales of 
the SCI are summarised in Table 6. Correlation of individual FACE-Q subscales with 
each other also confirmed the a priori hypotheses. ‘Satisfaction with facial 
appearance’ showed a strong positive correlation with ‘appearance of scars’ (r = 
0.619, p < 0.001). Higher ‘cancer worry’ correlated negatively with ‘satisfaction with 
facial appearance’ (r = - 0.292, p = 0.005), with this correlation present for both pre-
operative and post-operative questionnaires. Interestingly the hypothesis that those 
who had a greater number of post-operative symptoms would score worse on 
‘appearance of scars’ was also confirmed to be true (p = - 0.448, p < 0.001).    
 
Responsiveness 
 Data were skewed with a significant Kolmogorov-Smirnov test, therefore 
Wilcoxon signed rank tests were used to assess the data. Median scores were assessed 
between pre-operative and post-operative patients as all of these had undergone a 
change in their condition (i.e. surgery). ‘Satisfaction with facial appearance’ was non-
significantly reduced between pre- and post-operative assessment. A significant 
decrease in ‘cancer worry’ was seen. ‘Satisfaction with appearance information’ 
increased in the post-operative cohort although this was non-significant (Table 7). 




 There has been an identified need for a well-designed and validated PROM for 
those undergoing surgical treatment of a facial skin cancer. To develop a new PROM 
from the beginning is expensive, time consuming and potentially unnecessary34. If a 
PROM exists that can be adapted, either with the addition or removal of items and 
psychometric validation in the target population, this can have significant advantages. 
The PROMISCR study aimed to do this for the newly created FACE-Q Skin Cancer 
module.  
 The anglicisation process followed international consensus guidelines15,18, with 
a small number of changes required to convert it to UK English spelling and remove 
language that was not understandable to a different cultural population.  
 A number of interesting results were found during psychometric validation. A 
significant amount of missing data was seen, with up to 47% of patients not completing 
some items. There are a number of reasons why this could be the case, such as those 
questions being too difficult for people to answer or the feeling that they are repetitive 
of others. Internal consistency supports the view that the scales are reliable and 
homogenous with Cronbach’s alpha above 0.7 in all subscales. However, in some cases 
Cronbach’s alpha of ≥0.95 were seen, suggesting item redundancy. This was also the 
case for item-total correlation with many items having a Pearson’s r of >0.8, again 
suggesting item redundancy22,28. In combination with the high levels of missing data 
there is considerable evidence that the number of items in the FACE-Q Skin Cancer 
module should be reduced.  
 A significant ceiling effect was seen in all subscales apart from ‘cancer worry’ 
and ‘sun protection behaviour’. This means that a significant number of people are 
scoring the highest obtainable Rasch transformed score on these subscales, reducing 
responsiveness and interpretability of the scale. For example, if someone is to score the 
highest obtainable score and their condition changes, the instrument will only be able 
to detect this in one direction (i.e. a fall in scores). If the condition of these patients 
improves further however, it cannot be detected by the instrument. A floor or ceiling 
effect of greater than 15% is considered to be too high and may suggest that a scale is 
not functioning as intended23. One reason for the high scores seen could be that the 
patient population is generally very happy, however a range of EQ-5D-5L scores 
suggest that some people had lower levels of general HRQoL despite still scoring 
highly on the FACE-Q subscales. Acquiescence bias, in which there is a tendency to 
respond positively to all questions, may also be the cause of the high ceiling effects35. 
This is especially true for subscales that ask about feelings towards the staff treating 
the patient, where patients do not want to cause offence by answering negatively.  
 Principal component analysis (PCA) is a powerful analytical process for 
identifying factors within a group of items and those items that do not fit the model. All 
subscales were shown to be assessing a single underlying factor, with factor loading of 
greater than 0.4 for all items providing counter evidence to the assumption that the total 
items should be reduced.    
 The anglicised questionnaire demonstrated good construct validity (both 
convergent and divergent) with greater than 75% of the a priori hypotheses 
confirmed23. Responsiveness was identified in three subscales (satisfaction with facial 
appearance, cancer worry and satisfaction with appearance information). This suggests 
that these subscales are able to detect change in a patients’ condition, with further 
research and greater numbers required to confirm these results and identify if other 
subscales are also responsive. These results are similar to those described in the 
developers’ initial validation study, with significant floor and ceiling effects, good 
construct validity and responsiveness in the ‘cancer worry’ subscale also seen10.  
 It is acknowledged that using a single centre plastic surgery cohort could 
introduce bias, however the demographics of this patient group were representative of 
those patients with facial skin cancer across the UK. The population studied was varied, 
but drawn from a South Wales centre with many people from rural and deprived 
backgrounds. It is possible that many of these patients were more content with their 
treatment and outcomes than a more highly educated and less deprived population in a 
larger city in the southeast of England would be. The merits of classical test theory 
(CTT) versus modern test theory (MTT) have been discussed at length in the 
literature36,37. CTT was chosen in this validation work for a number of reasons. In early 
validation of an instrument (such as when a new instrument is designed or translation 
occurs), CTT can be very useful in identifying items for removal and exploring the 
underlying dimensions of a scale. The importance of using CTT in PROM validation 
(in conjunction with MTT) is borne out in the continued presence of CTT in guidelines 
such as the COSMIN checklist38,39 and those by Terwee et al23 and Prinsen et al40. In 
order to address the limitations of this study a second phase of validation work is 
underway, with a larger cohort of patients being recruited from a second site in England 
and planned Rasch analysis in line with the original instrument validation study.   
 
Conclusion  
 The anglicised FACE-Q Skin Cancer module appears to be a well designed 
and valid PROM with good construct validity and responsiveness in some subscales. 
With further refinement and validation, the anglicised FACE-Q Skin Cancer module 
will play an important role in collecting and analysing patient reported data on facial 
















Table 1 – Scenarios in which different degrees of cross-cultural adaptation are 
required. Adapted from Guillemin et al(19) and Beaton et al(41). 
 
 Results in a change in Adaptation required 




A) Use in same 
population. No 
change in culture, 
language or country 
-- -- -- -- -- 
B) Use in established 
immigrants in source 
country 
Yes -- -- -- Yes 
C) Use in another 
country, but same 
language 
Yes -- -- -- Yes 
D) Use in new 
immigrants, not 
source language 
speaking but in the 
source country 
Yes Yes -- Yes Yes 
E) Use in another 
country and another 
language 










Variable All patients (n=110) 
Age  
  Mean age (SD) 
  < 65 years of age 






  Male 





  Cardiovascular 
  Respiratory 
  Cancer (other than skin cancer) 
  Mental health 
  Musculoskeletal 
  Other 










  Warfarin 
  Aspirin 
  Clopidogrel 
  Other anticoagulation 
  Immunosuppression 
  Other 










  BCC 
  SCC 
  Melanoma 






  Other 




  Forehead 
  Eyelid 
  Nose 
  Lips 
  Medial cheek 
  Lateral face 










  Direct closure 
  Skin graft 





Previous facial surgery 
  Yes 




Previous skin cancer 
  Yes 














Table 3 – Range of missing data for each subscale of the FACE-Q Skin Cancer 
module and the Skin Cancer Index (SCI). 
 
Scale Subscale Range of missing 
data (%) 
FACE-Q Satisfaction with facial appearance 11.8 – 16.4 
Appearance of scars 41.8 – 47.3 
Cancer worry 3.6 – 7.4 
Satisfaction with information: appearance 25.5 – 30.9 
Satisfaction with doctor/surgeon 26.4 – 32.7 
Satisfaction with clerical staff 11.8 – 21.8 
Satisfaction with medical/ward team 26.4 – 30.9 
Satisfaction with information 25.5 – 40 
Sun protection behaviour 5.5 – 28.2 
Symptoms checklist 29.1 – 32.7 
SCI Emotional 6.4 – 10.9 
Social 9.1 – 10.9 












Table 4 – Floor and ceiling effects calculated for each subscale in the FACE-Q skin cancer module. 
 Pre-operative questionnaires 










73.3 21.9 0 – 100 74 -0.58 0.9% 22.7% 
Appearance of 
scars 
80.9 23.2 0 – 100 91 -1.18 0.9% 24.5% 




79.5 21.6 0 – 100 80 -0.88 0.9% 30% 
Satisfaction with 
doctor/surgeon 
92.8 15.0 0 – 100 100 -3.63 0.9% 49.1% 
Satisfaction with 
clerical staff 




95.7 11.0 44 – 100 100 -3.11 0% 57.3% 
Satisfaction with 
information 
82.5 18.7 40 – 100 90 -0.59 0% 29.1% 
Sun protection 
behavior* 
14.4 4.0 5 – 20 15 -0.31 0.9% 12.7% 
Symptoms 
checklist* 
15.6 6.8 10 – 40 13 1.49 19.1% 0.9% 
 
  







Table 5 – Principal component analysis (PCA) for individual subscales of the FACE-
Q Skin Cancer module. 
 













0.886 <0.001 1 6.591 73.2% 
Appearance of 
scars 
0.910 <0.001 1 6.267 78.3% 









































0.838 <0.001 1 3.350 67.0% 
Symptoms 
checklist 











* Monte Carlo PCA for Parallel Analysis was used to confirm the number of factors 
after Oblimin rotation for all sub-scales as per the methods. Three sub-scales initially 
had two factors, although this was reduced to one following parallel analysis.  
-- KMO/Bartlett’s could not be calculated as the matrix showed linear dependency with 









Table 6 – Summary of correlations between FACE-Q Skin Cancer module subscales 













- 0.756 57.2% < 
0.001 
A large negative correlation – as 
predicted due to the scoring of 
items in each scale (i.e. as FACE-
Q cancer worry increases (higher 
score) SCI cancer worry also 
increases (but higher worry is 





- 0.560 31.36% < 
0.001 
A large negative correlation – as 
predicted those people that are 
more worried by their skin cancer 
on the FACE-Q cancer subscale 














0.570 32.49 < 
0.001 
A large positive correlation – as 
predicted as better scores on 
FACE-Q appearance of scars 
indicate greater happiness with 
scars, along with increasing scores 
on SCI appearance subscale 
‘satisfaction 
with facial 
0.439 19.3% < 
0.001 
A medium positive correlation – as 




happiness with facial appearance 
on FACE-Q correlating with 
increasing happiness with 


































signed rank z 






91.0 78.0 z = - 1.177 
p = 0.239 
0.104 
Cancer worry 50 43 z = - 2.907 





80 92 z = - 0.299 




100 100 z = - 0.597 




100 100 z = - 0.691 




100 100 z = - 0.625 




90 90 z = - 0.049 
p = 0.961 
0.004 
Figure 1 – Anglicisation process applied to the FACE-Q Skin Cancer module 
following international guidelines. 
 
 
Supplementary Figure 1 – Changes made to the FACE-Q Skin Cancer module 
during the anglicisation process. 
 
 
Supplementary Figure 2 – Summary of readability scores for the anglicised FACE 
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